Tailoring Treatment Intensity in HNSCC: The Expanding Role of Cancer Immunotherapy - ABIM MOC Part 2 - Live
Webinar InformationWebinar Description Immunotherapy has become integrated into therapy for many solid tumors. As this new modality has evolved through recurrent/metastatic and recently into the locally advanced setting, new insights and dangers have been encountered, providing insights into complex interactions of conventional modalities with immunotherapeutic modulation of the tumor microenvironment and clinical benefit for patients. The roles of treatment intensification and de-intensification using immunotherapy will be discussed. Learning Objectives
Learning Outcomes
Learning Purpose
|
Webinar DocumentsHandouts Flyers Please feel free to share the flyer and/or this webpage. Poll Everywhere Link Please give poll responses via web at: |
Webinar RegistrationYou must have an account and be logged in to register for and to access the course. Please contact us with any questions at [email protected] or (919) 445–1000. |
![]() | The Lineberger Cancer Center Grand Rounds are educational activities regarding cancer. We cover the most relevant oncology topics. These webinars provide FREE continuing education credit. |
![]() | Robert L. Ferris, MD, PhD, FACS Executive Director |
DisclosuresActivity Directors ABIM MOC Part 2 Credit ACCME |
Accreditation Statements1.00 ABIM MOC Part 2 Credit 1.00 AMA PRA Category 1 Credit™ |
NoticeIn most cases, regulations prohibit the repeated use of the same educational activity (Live Webinar or Self-Paced, Online Course but not both) as it relates to satisfying CE requirements to maintain licensure. Attendees are also required to view a minimum of 53 minutes of the live webinar video to receive CE credit. Please contact your individual accreditation agencies for more details. Altering or submitting modified certificates constitutes fraud that can result in punitive action by the accrediting agency. |
Available Credit
- 1.00 ABIM Medical Knowledge
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation

Facebook
X
LinkedIn
Forward
